Panacos Pharmaceuticals, Inc.
PANC · OTC
9/30/2008 | 6/30/2008 | 3/31/2008 | 12/31/2007 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 33.3% | -48.6% | 59.1% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 100% | 100% | 100% | 100% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $0 | $0 | $0 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$0 | -$0 | -$0 | -$0 |
| Operating Expenses | -$0 | -$0 | -$0 | -$0 |
| Operating Income | $0 | $0 | $0 | $0 |
| % Margin | 31,545.8% | 51,205.6% | 23,371.4% | 42,068.2% |
| Other Income/Exp. Net | -$0 | -$0 | -$0 | -$0 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -33,966.7% | -54,122.2% | -24,320% | -42,495.5% |
| EPS | -0.15 | -0.18 | -0.16 | -0.175 |
| % Growth | 16.7% | -12.5% | 8.7% | – |
| EPS Diluted | -0.15 | -0.18 | -0.16 | -0.175 |
| Weighted Avg Shares Out | 0 | 0 | 0 | 0 |
| Weighted Avg Shares Out Dil | 0 | 0 | 0 | 0 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -30,233.3% | -49,477.8% | -22,508.6% | -40,727.3% |